California Proposition 38, set for the November 3, 2026 ballot, would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, directing at least half to cancer, heart disease, and Alzheimer’s while splitting proceeds between a designated University of California-affiliated institute and competitive grants. Trader consensus slightly favors passage at 57.5% for yes, reflecting endorsements from the California Democratic Party and disease advocacy organizations alongside precedents like prior stem cell bonds. Key factors include requirements for discounted treatments in the state, 10% revenue sharing to offset costs, and annual general fund repayments estimated at $500–600 million for roughly 20 years, with opposition centering on fiscal burden and the measure’s specific allocation structure. Early voting has begun, and the outcome hinges on voter priorities around research investment versus state debt.